挽救性全腺体冷冻消融治疗放疗抵抗性前列腺癌男性的肿瘤学与功能学结局
本文回顾性分析2002年1月至2019年9月在一家三级转诊中心接受挽救性全腺体冷冻消融(SWGC)的110例活检证实的放疗抵抗/复发性前列腺癌(RRPC)男性,中位随访71个月,2年无生化复发生存率为81%,5年为71%,Clavien-Dindo≥3级不良事件发生3例(2.7%)。
要点
- SWGC后2年无生化复发生存率为81%,5年为71%。
- SWGC后PSA谷值越高与更差的无生化复发生存相关。
- SWGC后3个月压力性尿失禁为5%,12个月为9%。
核心结论
- 在局限性放疗抵抗性前列腺癌患者中,SWGC取得了极好的肿瘤学结局和较低的尿失禁发生率,是挽救性根治性前列腺切除术的一种替代选择。
- 阳性穿刺针数更少和PSA更低的患者在接受SWGC后肿瘤学结局似乎更好。
- 对于放疗后持续存在前列腺癌的男性,对整个前列腺进行冷冻治疗可实现极好的癌症控制。
- 在此治疗后6年时PSA未升高的患者似乎已治愈。
研究设计与样本
- 回顾性分析一家三级转诊中心2002年1月至2019年9月前瞻性收集的冷冻手术数据库。
- 纳入110例经活检证实的放疗抵抗/复发性前列腺癌并接受挽救性全腺体冷冻消融的男性。
主要发现
- SWGC后无生化复发患者的中位随访时间为71个月(四分位距42.3-116)。
- 无生化复发生存率2年为81%,5年为71%。
- SWGC后PSA谷值越高与更差的无生化复发生存率相关。
- 国际勃起功能指数-5评分中位数SWGC前为5(四分位距1-15.5),SWGC后为1(四分位距1-4)。
- 压力性尿失禁(严格定义为治疗后使用任何尿垫)3个月为5%,12个月为9%;Clavien-Dindo≥3级不良事件发生于3例患者(2.7%)。
关键数值与推荐
- 主要结局为根据Phoenix标准判定的生化复发无生存率。
- 次要结局包括无转移生存率、癌症特异性生存率和不良事件。
临床怎么用
- 作者认为,对于局限性放疗抵抗性前列腺癌患者,SWGC是挽救性根治性前列腺切除术的一种替代选择。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no consensus on the optimal approach for salvage local therapy in radiation-resistant/recurrent prostate cancer (RRPC). OBJECTIVE: To investigate oncological and functional outcomes for men treated with salvage whole-gland cryoablation (SWGC) of the prostate for RRPC. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively reviewed our prospectively collected cryosurgery database between January 2002 and September 2019 for men who were treated with SWGC of the prostate at a tertiary referral center. INTERVENTION: SWGC of the prostate. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was biochemical recurrence-free survival (BRFS) according to the Phoenix criterion. Secondary outcomes included metastasis-free survival, cancer-specific survival, and adverse events. RESULTS AND LIMITATIONS: A total of 110 men with biopsy-proven RRPC were included in the study. Median follow-up for patients without biochemical recurrence (BCR) after SWGC was 71 mo (interquartile range [IQR] 42.3-116). BRFS was 81% at 2 yr and 71% at 5 yr. A higher prostate-specific antigen (PSA) nadir after SWGC was associated with worse BRFS. The median International Index of Erectile Function-5 score was 5 (IQR 1-15.5) before SWGC and 1 (IQR 1-4) after SWGC. Stress urinary incontinence, strictly defined as the use of any pads after treatment, was 5% at 3 mo and 9% at 12 mo. Clavien-Dindo grade ≥3 adverse events occurred in three patients (2.7%). CONCLUSIONS: In patients with localized RPPC, SWGC achieved excellent oncological outcomes with a low rate of urinary incontinence, and represents an alternative to salvage radical prostatectomy. Patients with fewer positive cores and lower PSA tended to have better oncological outcomes following SWGC. PATIENT SUMMARY: For men with prostate cancer that persists after radiotherapy, a freezing treatment applied to the whole prostate gland can achieve excellent cancer control. Patients who did not have elevated prostate-specific antigen (PSA) at 6 years after this treatment appeared to be cured.
引用
- Tan WP, Kotamarti S, Ayala A, et al. Oncological and Functional Outcomes for Men Undergoing Salvage Whole-gland Cryoablation for Radiation-resistant Prostate Cancer. Eur Urol Oncol. 2023. PMID: 36890104. doi:10.1016/j.euo.2023.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。